DaVita HealthCare Partners Inc
$ 117.28
-0.82%
04 Dec - close price
- Market Cap 8,454,875,000 USD
- Current Price $ 117.28
- High / Low $ 118.50 / 116.39
- Stock P/E 12.20
- Book Value -8.06
- EPS 9.69
- Next Earning Report 2026-02-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.62 %
- 52 Week High 179.60
- 52 Week Low 113.97
About
DaVita HealthCare Partners Inc. is a premier provider of kidney care services, renowned for its expansive network of outpatient dialysis centers throughout the United States. The company is dedicated to enhancing the quality of life for patients with chronic kidney disease by utilizing cutting-edge treatment technologies and innovative care delivery models. As a leader in the renal care sector, DaVita's integrated approach significantly improves patient outcomes, positioning it as a compelling investment opportunity for institutional investors focused on growth within the evolving healthcare landscape.
Analyst Target Price
$144.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-08-05 | 2025-05-12 | 2025-02-13 | 2024-10-29 | 2024-08-06 | 2024-05-02 | 2024-02-13 | 2023-11-07 | 2023-08-03 | 2023-05-08 | 2023-02-22 |
| Reported EPS | 2.51 | 2.95 | 2 | 2.24 | 2.59 | 2.5 | 2.26 | 1.62 | 2.62 | 1.91 | 1.25 | 0.59 |
| Estimated EPS | 3.18 | 2.75 | 2.02 | 2.13 | 2.72 | 2.54 | 1.95 | 1.59 | 2.02 | 1.69 | 1.15 | 0.91 |
| Surprise | -0.67 | 0.2 | -0.02 | 0.11 | -0.13 | -0.04 | 0.31 | 0.03 | 0.6 | 0.22 | 0.1 | -0.32 |
| Surprise Percentage | -21.0692% | 7.2727% | -0.9901% | 5.1643% | -4.7794% | -1.5748% | 15.8974% | 1.8868% | 29.703% | 13.0178% | 8.6957% | -35.1648% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 3.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DVA
2025-12-04 12:09:41
Schroder Investment Management Group reduced its stake in DaVita Inc. by 36% in the second quarter, selling 39,629 shares and now owning 70,431 shares worth approximately $10.03 million. Despite this, other institutions like Neuberger Berman and Norges Bank increased their holdings, leading to institutional ownership of about 90.12%. Analysts have a "Reduce" consensus rating with an average target price of $148.00, following DaVita's missed quarterly EPS and conservative FY2025 guidance.
2025-12-03 09:30:00
DaVita (DVA) is rated a speculative 'Buy' due to undervaluation and its dominant US dialysis network, despite earnings volatility and reliance on Medicare reimbursement. Trading below 11.5x P/E, DVA offers potential double-digit annual returns if it regains historical valuation multiples. Key risks include Medicare rate cuts, earnings misses, and high leverage, necessitating careful position sizing for risk-tolerant investors.
2025-12-02 15:35:00
DaVita (DVA) highlights its vision for leveraging technology to transform specialty care, addressing the fragmentation prevalent in chronic disease management. Joel Haugen, chief product officer, emphasized that specialty care accounts for 90% of medical spend and showcased DaVita Care Connect as an example of technology enhancing patient engagement, adherence, and overall experience. The company stresses the importance of designing user-friendly solutions for both patients and care teams, as well as fostering collaboration among stakeholders to scale these technological advancements.
2025-12-02 10:35:00
DaVita shared its vision for technology transformation in specialty care, emphasizing how technology can help address healthcare fragmentation for the 129 million Americans living with chronic conditions. Joel Haugen, Chief Product Officer for DaVita, highlighted the significant medical spend in specialty care and the potential of solutions like the DaVita Care Connect mobile app to enhance patient engagement through user-friendly interfaces. The article stresses the need for intentional change, prioritizing the experience of both patients and care teams, and fostering collaboration among stakeholders to scale solutions and reduce care fragmentation.
2025-11-30 16:36:33
This page provides financial data for DaVita Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh (DVAI34) on TradingView, specifically focusing on tangible book value per share. It displays market status, links to supercharts and various financial overview sections, and details data source attributions for market and reference information.
2025-11-27 16:53:36
This page provides financial data specifically focusing on the "Book value per share" for DaVita Inc. (GETTEX:TRL). It indicates that the market for DaVita Inc. is currently closed and no trades are available for viewing on this particular page. The content suggests further exploration on Supercharts for more detailed financial analysis, news, and ideas related to the company.
